Kringle Pharma and Maruishi Pharmaceutical enter into a capital and business partnership for KP-100IT in acute spinal cord injury.

Kringle Pharma and Maruishi Pharmaceutical enter into a capital and business partnership for KP-100IT in acute spinal cord injury.